[1] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版). 临床肝胆病杂志,2019, 35:38-44.
[2] 段钟平, 陈煜. 目前人工肝发展面临的问题与挑战. 药品评价, 2007, 4(1): 1-3.
[3] 张红玉, 崔慧斐. 肝素药理作用和药物制剂的研究新进展. 中国药学杂志, 2019, 54(22): 1831-1839.
[4] 史旭波, 胡大一. 肝素的抗凝机制及临床相关问题. 临床荟萃, 2007, 22(18): 1293-1295.
[5] Mulloy B, Hogwood J, Gray E, et al. Pharmacology of heparin and related drugs. Pharmacol Rev, 2016,68(1):76-141.
[6] Lima M, Rudd T, Yates E. New applications of heparin and other glycosaminoglycans. Molecules, 2017,22(5):749.
[7] Beurskens D, Huckriede J, Schrijver R, et al. The anticoagulant and nonanticoagulant properties of heparin. Thrombosis and Haemostasis, 2020,120(10):1371-1383.
[8] Esmon CT. The protein C pathway. Chest, 2003,124(3 Suppl):26s-32s.
[9] 陈煜, 段钟平, 韩涛, 等. 人工肝血液净化技术临床应用专家共识(2022年版). 临床肝胆病杂志, 2022, 38(4): 767-775.
[10] 孔明, 周莉, 陈煜, 等. 双重血浆分子吸附系统治疗过程中肝素抗凝效果的影响因素研究. 首都医科大学学报, 2021, 42(4): 647-652.
[11] Qiu M, Huang S, Luo C, et al. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed Pharmacother, 2021,139:111561.
[12] (日)野入英世,(日)花房规男.血液净化疗法手册. 任庆华,译. 北京:北京科学技术出版社, 2013.
[13] 陈煜, 段钟平, 刘义荣, 等. 监测APTT指导重型肝炎患者人工肝治疗的肝素用量. 中国血液净化, 2004, 3(9):493-495.
[14] 汪燕. 新型抗凝药物研究进展. 中国新药杂志, 2011, 20(6): 514-517.
[15] 高飞, 李烨, 曾晖, 等. 不同肝素钠抗凝治疗方案在肝衰竭患者血浆置换中的比较研究. 中国现代医学杂志, 2022, 32(3): 70-73.
[16] 闫国胜, 张宏涛, 鲁杨, 等. 血浆吸附治疗肝衰竭肝素抗凝方案的临床研究. 中华肝脏病杂志, 2022, 30(7): 716-721.
[17] Oudemans-van Straaten HM, Wester JPJ, de Pont A, et al. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med, 2006,32(2):188-202.
[18] Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis, 2012,60(3):473-486.
[19] 赵宇亮, 买红霞, 付平. 血液净化抗凝方式的选择. 临床肾脏病杂志, 2018, 18(4): 196-199.
[20] 颜明明, 刘利月, 戴婷婷, 等. 低分子肝素类药物的临床应用. 中国医药指南, 2018, 16(18): 39-40.
[21] Signorelli SS, Scuto S, Marino E, et al. Anticoagulants and Osteoporosis. Int J Mol Sci, 2019,20(21):5275.
[22] 刘章, 姬胜利, 王凤山. 低分子肝素的药理作用和临床应用研究进展. 药物生物技术, 2014, 21(6): 573-578.
[23] Hao C, Sun M, Wang H, et al. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci, 2019,163:21-39.
[24] 杨鑫, 刘小静, 许娟, 等. 基于体重和凝血酶原时间的不同剂量低分子肝素对重症肝病患者血浆置换治疗的效果分析. 临床药物治疗杂志, 2020, 18(7): 37-41.
[25] 张洁, 赵成燕, 郑嵘炅, 等. 不同抗凝药物在双重胆红素吸附联合血浆置换对肝衰竭的治疗效果及安全性比较. 新疆医科大学学报, 2022, 45(2): 150-154.
[26] 潘业, 欧宏杰, 曾建勇, 等. 血浆置换术中普通肝素及低分子肝素钠的应用分析. 中国医学工程, 2015, 23(1): 96-97.
[27] 李桂凤, 文跃莲. 改良预冲法在无肝素血浆置换病人中的应用效果. 护理研究, 2019, 33(17): 3029-3031.
[28] 袁素娥, 周阳, 谭德明, 等. 肝素在分子吸附再循环治疗肝衰竭中的应用及对凝血指标的影响. 中南大学学报(医学版), 2011, 36(9): 830-835.
[29] 周芸. 无肝素人工肝血浆置换术治疗肝功能衰竭的临床观察及护理. 实用临床医药杂志, 2017, 21(8): 46-48.
[30] 李桂凤, 钟美容, 杨丽岚, 等. 改良预冲法在个体化抗凝人工肝双重血浆分子吸附术中的应用效果. 广西医学, 2021, 43(10): 1260-2+6.
[31] Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care, 2017,21(1):281.
[32] Klingele M, Stadler T, Fliser D, et al. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care, 2017,21(1):294.
[33] 李晓冉, 马元吉, 白浪, 等. 局部枸橼酸抗凝在单重血浆置换治疗中的应用研究进展. 中华临床感染病杂志, 2021, 14(6): 475-480.
[34] Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med, 2003,31(10):2450-2455.
[35] Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care, 2007,11(4):218.
[36] 马元吉, 陈芳, 许艳, 等. 局部枸橼酸抗凝在血浆吸附联合血浆置换治疗高危出血倾向肝衰竭患者中的应用. 世界华人消化杂志, 2018, 26(3): 165-173.
[37] 王临旭, 刘浩, 党肖, 等. 局部枸橼酸抗凝在DPMAS联合低置换量血浆置换治疗慢加急性肝衰竭患者中的应用. 现代生物医学进展, 2021, 21(14): 2748-52+800.
[38] Strobl K, Harm S, Fichtinger U, et al. Impact of anion exchange adsorbents on regional citrate anticoagulation. Int J Artif Organs, 2021,44(3):149-155.
[39] Lion RP, Tufan Pekkucuksen N, Srivaths P, et al. The safety and efficacy of regional citrate anticoagulation in albumin-assisted liver dialysis for extracorporeal liver support in pediatric patients. Blood Purif, 2019,47(1-3):23-27.
[40] Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care, 2019,23(1):22.
[41] Patel S, Wendon J. Regional citrate anticoagulation in patients with liver failure--time for a rethink? Crit Care, 2012,16(5):153.
[42] 刘志艳, 向倩, 崔一民. 甲磺酸萘莫司他临床应用的研究现状. 中国临床药理学杂志, 2020, 36(15): 2368-2372.
[43] Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol, 1984,35(3):203-227.
[44] Fuse I, Higuchi W, Toba K, et al. Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets, 1999,10(4):212-218.
[45] Lim JY, Kim JB, Choo SJ, et al. Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin. Ann Thorac Surg, 2016,102(2):534-539.
[46] Akizawa T, Koshikawa S, Ota K, et al. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron, 1993,64(3):376-381.
[47] Hwang SD, Hyun YK, Moon SJ, et al. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs, 2013,36(3):208-216.
[48] Nakae H, Igarashi T, Tajimi K. The dose of nafamostat mesilate during plasma exchange with continuous hemodiafiltration in the series-parallel circuit. Ther Apher Dial, 2006,10(3):233-236.
[49] Choi JY, Kang YJ, Jang HM, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore), 2015,94(52):e2392.
[50] Makino S, Egi M, Kita H, et al. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs, 2016,39(1):16-21.
[51] Park JH, Her C, Min HK, et al. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs, 2015,38(11):595-599.
[52] Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol, 1995,26(8):1627-1632.
[53] Willers A, Arens J, Mariani S, et al. New trends, advantages and disadvantages in anticoagulation and coating methods used in extracorporeal life support devices. Membranes (Basel), 2021,11(8):617. |
